The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease
Open accessAbstract
Accumulation of amyloid-beta (Abeta) is one of the earliest molecular events in Alzheimer disease (AD), whereas tau pathology is thought to be a later downstream event. It is now well established that Abeta exists as monomers, oligomers, and fibrils. To study the temporal profile of Abeta oligomer formation in vivo and to determine their interaction with tau pathology, we used the 3xTg-AD mice, which develop a progressive accumulation of plaques and tangles and cognitive impairments. We show that SDS-resistant Abeta oligomers accumulate in an age-dependent fashion, and we present evidence to show that oligomerization of Abeta appears to first occur intraneuronally. Finally, we show that a single intrahippocampal injection of a specific oligomeric antibody is sufficient to clear Abeta pathology, and more importantly, tau pathology. Therefore, Abeta oligomers may play a role in the induction of tau pathology, making the interference of Abeta oligomerization a valid therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both Aβ and tau exhibit age- and region-dependent formation in these mice, with Aβ plaques appearing prior to tangles, which are extensive in older transgenic mice.”
From Brain microstructure abnormalities in the 3xTg-AD mouse – A diffusion MRI and morphology correlation study (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In our morphological analysis (Fig. 2 and 3), as previously described [3–6, 28], Aβ plaque and tau pathology are evident in 15-month-old TG mice, and significantly increased with age (online supplementary Fig.1 and 2).”
From Brain microstructure abnormalities in the 3xTg-AD mouse – A diffusion MRI and morphology correlation study (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It develops both amyloid-β (Aβ) and neurofibrillary tangles in a temporal and spatial pattern similar to human AD pathology [3–6].”
From Brain microstructure abnormalities in the 3xTg-AD mouse – A diffusion MRI and morphology correlation study (2022) · cites this paper as [4]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Additionally, due to the variability of the degree of AD pathology described in this model [4, 6, 26], large ROIs, as used for the HD and HV, may have attenuated some effects.”
From Brain microstructure abnormalities in the 3xTg-AD mouse – A diffusion MRI and morphology correlation study (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“the ability of antibodies to reverse intracellular tau and synapse pathology (Chauhan et al., 2008; Oddo et al., 2006) and to provide cognitive benefits (Hillen et al., 2010; Takamura et al., 2011).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Oddo et al., 2006
In the citing paper
“Synapse deterioration in tg-mice is prevented by ICV injections of oligomer-specific antibodies (Chauhan, 2007; Oddo et al., 2006).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Oddo et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Self-citationCommon structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Self-citationDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citationAlzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
Research works printed but not linked: 1
- Oddo, 2006, Am. J. Pathol.
Cited by
Sorted by citations
Items 101–200 of 380
Currais, A. J. M., Fischer, W. H., Maher, P. A., & Schubert, D. A. (2016) · The FASEB Journal · doi:10.1096/fj.201601184 · Cited by 120
Evidence for Age-Dependent in Vivo Conformational Rearrangement within Aβ Amyloid Deposits
Nyström, S., Psonka-Antonczyk, K. M., Ellingsen, P. G., Johansson, L. B. G., Reitan, N. K., Handrick, S., Prokop, S., Heppner, F. L., Wegenast‐Braun, B. M., Jucker, M., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4000376 · Cited by 114
Hoffman, J. L., Faccidomo, S., Kim, M., Taylor, S. M., Agoglia, A. E., May, A. M., Smith, E. N., Wong, L. C., & Hodge, C. W. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.10.017 · Cited by 113
The role of amyloid β in the pathogenesis of Alzheimer's disease
Gilbert, B. J. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201515 · Cited by 109
Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease
Klein, W. L. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.11.003 · Cited by 109
Self-citationOh, K.-J., Perez, S. E., Lagalwar, S., Vana, L., Binder, L., & Mufson, E. J. (2010) · International Journal of Alzheimer's Disease · doi:10.4061/2010/780102 · Cited by 105
Back to the Future with Phenotypic Screening
Prior, M., Chiruta, C., Currais, A. J. M., Goldberg, J., Ramsey, J., Dargusch, R., Maher, P. A., & Schubert, D. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500051h · Cited by 102
Regenerative potential of allopregnanolone
Wang, J. M., Liu, L., Irwin, R. W., Chen, S., & Brinton, R. D. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.08.010 · Cited by 103
Bridging the gap: From protein misfolding to protein misfolding diseases
Luheshi, L. M., & Dobson, C. M. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.06.030 · Cited by 101
Acat1 Knockdown Gene Therapy Decreases Amyloid-β in a Mouse Model of Alzheimer's Disease
Murphy, S. R., Chang, C. C., Dogbevia, G., Bryleva, E. Y., Bowen, Z., Hasan, M. T., & Chang, T.-Y. (2013) · Molecular Therapy · doi:10.1038/mt.2013.118 · Cited by 96
Immunotherapy for Alzheimer's disease
Wısnıewskı, T., & Goñi, F. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.020 · Cited by 103
Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease
Cassano, T., Serviddio, G., Gaetani, S., Romano, A., Dipasquale, P., Cianci, S., Bellanti, F., Laconca, L., Romano, A. D., Padalino, I., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.021 · Cited by 102
Self-citationReduction of β-amyloid and γ-secretase by calorie restriction in female Tg2576 mice
Schafer, M. J., Alldred, M. J., Lee, S. H., Calhoun, M. E., Petkova, E., Mathews, P. M., & Ginsberg, S. D. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.043 · Cited by 97
Iijima, K., Gatt, A., & Iijima-Ando, K. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq200 · Cited by 96
Ye, M., Chung, H., Lee, C., Yoon, M. S., Yu, A., Kim, J. S., Hwang, D., Shim, I., & Bae, H. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0476-z · Cited by 97
Amyloid-β Immunotherapy for Alzheimers Disease
Fu, H., Liu, B., Frost, J. L., & Lemere, C. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012017 · Cited by 92
A Ganglioside-induced Toxic Soluble Aβ Assembly
Yamamoto, N., Matsubara, E., Maeda, S., Minagawa, H., Takashima, A., Maruyama, W., Michikawa, M., & Yanagisawa, K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606202200 · Cited by 96
Low‐n oligomers as therapeutic targets of Alzheimer’s disease
Ono, K., & Yamada, M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07187.x · Cited by 76
Medeiros, R., Kitazawa, M., Chabrier, M. A., Cheng, D., Baglietto‐Vargas, D., Kling, A., Möller, A., Green, K. N., & LaFerla, F. M. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.04.020 · Cited by 92
Self-citationRahimi, F., Shanmugam, A., & Bitan, G. (2008) · Current Alzheimer Research · doi:10.2174/156720508784533358 · Cited by 88
APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy
Breyhan, H., Wirths, O., Duan, K., Marcello, A., Rettig, J., & Bayer, T. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0539-7 · Cited by 87
Pitt, J. E., Wilcox, K. C., Tortelli, V., Diniz, L. P., Oliveira, M. S., Dobbins, C., Yu, X., Nandamuri, S., Gomes, F. C. A., DiNunno, N., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-06-0416 · Cited by 87
Self-citationVieira, M. N. N., Forny‐Germano, L., Saraiva, L. M., Sebollela, A. S., Martinez, A. M. B., Houzel, J., Felice, F. G. D., & Ferreira, S. T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04809.x · Cited by 85
Aβ solubility and deposition during AD progression and in APP × PS-1 knock-in mice
Murphy, M. P., Beckett, T. L., Ding, Q., Patel, E., Markesbery, W. R., Clair, D. K. S., LeVine, H., & Keller, J. N. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.06.002 · Cited by 87
Autoimmune Manifestations in the 3xTg-AD Model of Alzheimer's Disease
Marchese, M., Cowan, D., Head, E., Ma, D., Karimi, K., Ashthorpe, V., Kapadia, M., Zhao, H., Davis, P., & Sakic, B. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131490 · Cited by 94
Heo, C., Chang, K., Choi, H. S., Kim, H., Kim, S., Liew, H., Kim, J. A., Yu, E., Ma, J., & Suh, Y. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04499.x · Cited by 86
Potential pathogenic role of β-amyloid1–42–aluminum complex in Alzheimer's disease
Drago, D., Bettella, M., Bolognin, S., Cendron, L., Ščančar, J., Milačić, R., Ricchelli, F., Casini, A., Luigi Messori, A., Tognon, G., et al. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.10.014 · Cited by 82
Endoplasmic Reticulum Enrollment in Alzheimer’s Disease
Viana, R. J. S., Nunes, A. F., & Rodrigues, C. M. P. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8301-x · Cited by 82
Biella, G., Fusco, F., Nardo, E., Bernocchi, O., Colombo, A. V., Lichtenthaler, S. F., Forloni, G., & Albani, D. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151135 · Cited by 82
Amyloid β Modification: A Key to the Sporadic Alzheimer's Disease?
Barykin, E. P., Mitkevich, V. A., Kozin, S. A., & Makarov, A. А. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00058 · Cited by 84
Amyloid β‐induced astrogliosis is mediated by β1‐integrin via NADPH oxidase 2 in Alzheimer's disease
Wyssenbach, A., Quintela‐López, T., Llavero, F., Zugaza, J. L., Matute, C., & Alberdi, E. M. (2016) · Aging Cell · doi:10.1111/acel.12521 · Cited by 81
Murine models of Alzheimer's disease and their use in developing immunotherapies
Wısnıewskı, T., & Sigurdsson, E. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.05.004 · Cited by 84
Guan, H., Liu, Y., Daily, A., Police, S. B., Kim, M.-H., Oddo, S., LaFerla, F. M., Pauly, J. R., Murphy, M. P., & Hersh, L. B. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21944 · Cited by 80
Self-citationOddo, S., Caccamo, A., Cheng, D., Jouleh, B., Torp, R., & LaFerla, F. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04607.x · Cited by 79
Self-citationIslet amyloid polypeptide: Another key molecule in Alzheimer’s pathogenesis?
Zhang, Y., & Song, W. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.001 · Cited by 79
Amyloid-β and Tau Pathology of Alzheimer's Disease Induced by Diabetes in a Rabbit Animal Model
Bitel, C. L., Kasinathan, C., Kaswala, R. H., Klein, W. L., & Frederikse, P. H. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120571 · Cited by 78
Self-citationBlocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer’s disease
Epis, R., Marcello, E. E., Gardoni, F., Vastagh, C., Malinverno, M., Balducci, C., Colombo, A. V., Borroni, B., Vara, H., Dell’Agli, M., et al. (2010) · Brain · doi:10.1093/brain/awq217 · Cited by 83
Head, E. (2010) · AGE · doi:10.1007/s11357-010-9183-3 · Cited by 81
Rasool, S., Martínez‐Coria, H., Wu, J., LaFerla, F. M., & Glabe, C. G. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12305 · Cited by 74
Self-citationDrago, D., Cavaliere, A., Mascetra, N., Ciavardelli, D., Ilio, C. D., Zatta, P. F., & Sensi, S. L. (2008) · Rejuvenation Research · doi:10.1089/rej.2008.0761 · Cited by 74
Shen, L., Chen, C., Yang, A., Chen, Y., Liu, Q., & Ni, J. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.04.005 · Cited by 73
Oxidative stress induces macroautophagy of amyloid β-protein and ensuing apoptosis
Zheng, L. P., Kågedal, K., Dehvari, N., Benedikz, E., Cowburn, R. F., Marcusson, J. O., & Terman, A. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.10.043 · Cited by 74
Endogenous Aβ causes cell death via early tau hyperphosphorylation
Amadoro, G., Corsetti, V., Ciotti, M. T., Florenzano, F., Capsoni, S., Amato, G., & Calissano, P. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.06.005 · Cited by 74
Joshi, Y. B., & Praticò, D. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00436 · Cited by 75
Talwar, P., Sinha, J., Grover, S., Rawat, C., Kushwaha, S. S., Agarwal, R., Taneja, V., & Kukreti, R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9390-0 · Cited by 71
Hashimoto, T., Adams, K. W., Fan, Z., McLean, P. J., & Hyman, B. T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.257378 · Cited by 71
Modulation of 5-Lipoxygenase in Proteotoxicity and Alzheimer's Disease
Valera, E., Dargusch, R., Maher, P. A., & Schubert, D. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5183-12.2013 · Cited by 70
Kitazawa, M., Green, K. N., Caccamo, A., & LaFerla, F. M. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051232 · Cited by 73
Self-citationLee, S., Lemere, C. A., Frost, J. L., & Shea, T. B. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111025 · Cited by 68
Kiyota, T., Yamamoto, M., Schroder, B., Jacobsen, M. T., Swan, R. J., Lambert, M. P., Klein, W. L., Gendelman, H. E., Ransohoff, R. M., & Ikezu, T. (2009) · Molecular Therapy · doi:10.1038/mt.2009.44 · Cited by 69
Self-citationMattsson, N., Blennow, K., & Zetterberg, H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04944.x · Cited by 69
Yamamoto, K., Ueta, Y., Wang, L., Yamamoto, R., Inoue, N., Inokuchi, K., Aiba, A., Yonekura, H., & Kato, N. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.6752-10.2011 · Cited by 69
Picone, P., Giacomazza, D., Vetri, V., Carrotta, R., Militello, V., Biagio, P. L. S., & Carlo, M. D. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00724.x · Cited by 67
Role of Calcium in the Pathogenesis of Alzheimer’s Disease and Transgenic Models
Green, K. N., Smith, I. F., & LaFerla, F. M. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6191-2_19 · Cited by 67
Self-citationAβ, tau and ApoE4 in Alzheimer's disease: the axonal connection
Adalbert, R., Gilley, J., & Coleman, M. P. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.02.004 · Cited by 65
Increasing CSF phospho-tau levels during cognitive decline and progression to dementia
Andersson, C., Blennow, K., Almkvist, O., Andreasen, N., Engfeldt, P., Johansson, S., Lindau, M. P., & Eriksdotter, M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.027 · Cited by 65
Amyloid and Alzheimer's Disease: Inside and Out
Tam, J. H. K., & Pasternak, S. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013408 · Cited by 64
Kuo, Y., Lin, C.-Y., Li, J., & Lou, Y.-I. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s128396 · Cited by 64
Targeting β-Amyloid Pathology in Alzheimer's Disease with Aβ Immunotherapy
Nitsch, R. M., & Höck, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.013 · Cited by 62
Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis
Walton, C. C., Begelman, D. V., Nguyen, W., & Andersen, J. K. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00129 · Cited by 62
Endocytic pathways mediating oligomeric Aβ42 neurotoxicity
Yu, C., Nwabuisi‐Heath, E., Laxton, K., & LaDu, M. J. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-19 · Cited by 63
Picone, P., Nuzzo, D., & Carlo, M. D. (2013) · Biological Bulletin · doi:10.1086/bblv224n1p18 · Cited by 61
Emerging Proof of Protein Misfolding and Interactions in Multifactorial Alzheimer's Disease
Uddin, M. S., Mamun, A. A., Rahman, M. A., Behl, T., Perveen, A., Hafeez, A., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200601161703 · Cited by 59
A 2-process model for neuropathology of Alzheimer's disease
Mungas, D., Tractenberg, R., Schneider, J. A., Crane, P. K., & Bennett, D. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.007 · Cited by 58
Ubiquitin binds the amyloid β peptide and interferes with its clearance pathways
Bellia, F., Lanza, V., García‐Viñuales, S., Ahmed, I. M. M., Pietropaolo, A., Iacobucci, C., Malgieri, G., D’Abrosca, G., Fattorusso, R., Nicoletti, V. G., et al. (2019) · Chemical Science · doi:10.1039/c8sc03394c · Cited by 60
Regeneration in a Degenerating Brain: Potential of Allopregnanolone as a Neuroregenerative Agent
Wang, J., Irwin, R. W., Liu, L., Chen, S., & Brinton, R. D. (2007) · Current Alzheimer Research · doi:10.2174/156720507783018262 · Cited by 59
Klingstedt, T., & Nilsson, K. P. R. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120009 · Cited by 56
Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer’s disease?
Mielke, M. M., & Haughey, N. J. (2012) · Clinical Lipidology · doi:10.2217/clp.12.59 · Cited by 56
Synaptic vesicle cycle and amyloid β: Biting the hand that feeds
Ovsepian, S. V., O’Leary, V. B., Záborszky, L., Ntziachristos, V., & Dolly, J. O. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.01.011 · Cited by 57
Brain-Derived Neurotrophic Factor: the Link Between Amyloid-β and Memory Loss
Fahnestock, M. L. (2011) · Future Neurology · doi:10.2217/fnl.11.44 · Cited by 57
Braidy, N., Guillemin, G. J., & Grant, R. (2008) · Neurotoxicity Research · doi:10.1007/bf03033501 · Cited by 55
Senescence-Accelerated Mice P8: A Tool to Study Brain Aging and Alzheimer's Disease in a Mouse Model
Pallàs, M. (2012) · ISRN Cell Biology · doi:10.5402/2012/917167 · Cited by 57
Jiang, X., Chai, G., Wang, Z.-H., Hu, Y., Li, X., Ma, Z., Wang, Q., Wang, J., & Liu, G. (2015) · Scientific Reports · doi:10.1038/srep09488 · Cited by 55
Chierrito, T. P. C., Mantoani, S. P., Roca, C., Requena-Triguero, C., Sebastián-Pérez, V., Ordoñez, W. O. C., Moreira, N. C. D. S., Pérez, C., Sakamoto‐Hojo, E. T., Takahashi, C. S., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.051 · Cited by 54
Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons
Shughrue, P. J., Acton, P. J., Breese, R., Zhao, W., Chen-Dodson, E., Hepler, R. W., Wolfe, A. L., Matthews, M., Heidecker, G. J., Joyce, J. G., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.003 · Cited by 53
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease
Basi, G. S., Hemphill, S. S., Brigham, E. F., Liao, A., Aubele, D. L., Baker, J., Barbour, R., Bova, M. P., Chen, X., Dappen, M. S., et al. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt60 · Cited by 53
Kulic, L., McAfoose, J., Welt, T., Tackenberg, C., Späni, C. B., Wirth, F., Finder, V. H., Konietzko, U., Giese, M., Eckert, A., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.109 · Cited by 51
Self-citationVaccination as a Therapeutic Approach to Alzheimer's Disease
Wısnıewskı, T., & Boutajangout, A. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20156 · Cited by 53
Zhang, X., Wang, X., Zhou, T., Wu, X., Peng, Y., Zhang, W., Li, S., & Zhao, J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00227 · Cited by 53
Kuo, Y., & Rajesh, R. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.039 · Cited by 52
Liu, B., Frost, J. L., Sun, J., Fu, H., Grimes, S., Blackburn, P., & Lemere, C. A. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5924-12.2013 · Cited by 50
Oligomers of β-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model
Gaspar, R. C., Villarreal, S. A., Bowles, N. P., Hepler, R. W., Joyce, J. G., & Shughrue, P. J. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.001 · Cited by 53
Intrinsic Determinants of Neurotoxic Aggregate Formation by the Amyloid β Peptide
Brorsson, A., Bolognesi, B., Tartaglia, G. G., Shammas, S. L., Favrin, G., Watson, I. E., Lomas, D. A., Chiti, F., Vendruscolo, M., Dobson, C. M., et al. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2009.12.4320 · Cited by 52
Key Peptides and Proteins in Alzheimer’s Disease
Penke, B., Bogár, F., Paragi, G., Gera, J., & Fülöp, L. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190103123434 · Cited by 51
Rosenberg, R. N., Fu, M., & Lambracht‐Washington, D. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0441-4 · Cited by 50
Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities
Li, S., & Stern, A. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01589-5 · Cited by 47
Genetic Mouse Models of Neurodegenerative Diseases
Trancikova, A. K., Ramonet, D., & Moore, D. J. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-384878-9.00012-1 · Cited by 47
Jahnke, H., Rothermel, A., Sternberger, I., Mack, T. G. A., Kurz, R., Pänke, O., Striggow, F., & Robitzki, A. A. (2009) · Lab on a Chip · doi:10.1039/b819754g · Cited by 46
Sudol, K. L., Mastrangelo, M. A., Narrow, W. C., Frazer, M. E., Levites, Y., Golde, T. E., Federoff, H. J., & Bowers, W. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.174 · Cited by 50
Momtaz, S., Memariani, Z., El‐Senduny, F. F., Sanadgol, N., Golab, F., Katebi, M., Abdolghaffari, A. H., Farzaei, M. H., & Abdollahi, M. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00361 · Cited by 46
Amyloid and Tau accumulate in the brains of aged hydrocephalic rats
Silverberg, G. D., Miller, M. C., Machan, J. T., Johanson, C. E., Caralopoulos, I. N., Pascale, C. L., Heile, A., & Klinge, P. M. (2010) · Brain Research · doi:10.1016/j.brainres.2009.12.065 · Cited by 43
Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers
Nogalska, A., D’Agostino, C., Engel, W. K., Klein, W. L., & Askanas, V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0737-3 · Cited by 42
Self-citationBrainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's disease
Overk, C., Kelley, C. M., & Mufson, E. J. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.06.004 · Cited by 42
Pérez, J. L. M., Carrero, I., Gonzalo, P., Arévalo‐Serrano, J., Anquela, J. M. S., Ortega, F. J., Rodríguez, M. J., & Gonzalo‐Ruiz, A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.10.013 · Cited by 44
Corsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 42
Independent Effects of Intra- and Extracellular Aβ on Learning-Related Gene Expression
Wegenast‐Braun, B. M., Maisch, A. F., Eicke, D., Radde, R., Herzig, M. C., Staufenbiel, M., Jucker, M., & Calhoun, M. E. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090044 · Cited by 40
Failure of Ubiquitin Proteasome System: Risk for Neurodegenerative Diseases
Chen, Z., Geetha, T., & Babu, J. R. (2014) · Neurodegenerative Diseases · doi:10.1159/000367694 · Cited by 42
Suppression of Amyloid β A11 Antibody Immunoreactivity by Vitamin C
Cheng, F., Cappai, R., Ciccotosto, G. D., Svensson, G., Multhaup, G., Fransson, L., & Mani, K. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.243345 · Cited by 39
Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models
Wısnıewskı, T., & Boutajangout, A. (2009) · Brain Structure and Function · doi:10.1007/s00429-009-0236-2 · Cited by 39
Murphy, K. E., Llewellyn, K., Wakser, S., Pontasch, J., Samanich, N., Flemer, M., Hensley, K., Kim, D., & Park, J. C. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001245 · Cited by 38
Metadata
- Authors
- Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., & LaFerla, F. M.
- Affiliations
- University of California, Irvine (US)
- Northwestern University (US)
- Corresponding author
- LaFerla, Frank M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 281
- Issue
- 3
- Pages
- 1599-1604
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2020497815
- Cited by
- 379
- References
- 41
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 5 · 2022: 9 · 2021: 8 · 2020: 12 · 2019: 13 · 2018: 14 · 2017: 16 · 2016: 17 · 2015: 15 · 2014: 21 · 2013: 21 · 2012: 22
- FWCI
- 18.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Larry L. Hillblom Foundation
- National Institutes of Health (AG00538)
- National Institute on Aging (AG-11385, AG18877, AG0212982, AG 00538, AG 22547, R01AG022547, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease, 3xTg-AD mice, tau pathology, age-dependent accumulation, intrahippocampal injection, amyloid plaques, cognitive impairment, therapeutic target
- MeSH terms
- Aging, Alzheimer Disease, Animals, Disease Models, Animal, Hippocampus, Humans, Functional Laterality, Mice, Transgenic, Neurons, Recombinant Proteins, Amyloid beta-Peptides, tau Proteins, Macromolecular Substances, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
